Enabling Rapid Cell Line Screening To Reach Results Faster

This content is brought to you by Molecular Devices, a Danaher Operating Company.

Monoclonal antibody (mAb) based therapies offer effective treatments for conditions such as cancer and autoimmune diseases, but their development is hindered by the time and cost of cell line establishment. Traditional cell line screening methods are laborious and time-consuming. High-throughput screening and automated methods for IgG quantification, such as Beckman Coulter Life Sciences’ Valita Titer IgG Quantitation assay and Molecular Devices SpectraMAX iD5 plate reader, provide faster and more accurate identification of viable cell lines. These efficient, cost-effective solutions can accelerate cell line development and present new opportunities for drug discovery.